Case Report: A Case of Pituitary Carcinoma Treated With Sequential Dual Immunotherapy and Vascular Endothelial Growth Factor Inhibition Therapy
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Case Report: A Case of Pituitary Carcinoma Treated With Sequential Dual Immunotherapy and Vascular Endothelial Growth Factor Inhibition Therapy
Authors
Keywords
-
Journal
Frontiers in Endocrinology
Volume 11, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2020-11-18
DOI
10.3389/fendo.2020.576027
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Exploring the Role of Novel Medical Therapies for Aggressive Pituitary Tumors: A Review of the Literature—“Are We There Yet?”
- (2020) Lydia S. Lamb et al. Cancers
- Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
- (2020) Richard S. Finn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Temozolomide therapy for aggressive pituitary tumours – current understanding and future perspectives
- (2020) Pia Burman et al. REVIEWS IN ENDOCRINE & METABOLIC DISORDERS
- Apatinib (YN968D1) and temozolomide in recurrent invasive pituitary adenoma: case report and literature review
- (2019) Yong Wang et al. World Neurosurgery
- Modulation of temozolomide dose differentially affects T-cell response to immune checkpoint inhibition
- (2019) Aida Karachi et al. NEURO-ONCOLOGY
- Crosslink between Temozolomide and PD-L1 immune-checkpoint inhibition in glioblastoma multiforme
- (2019) Sabrina Heynckes et al. BMC CANCER
- Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment
- (2019) Ming Yi et al. Molecular Cancer
- Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
- (2019) Filipe Martins et al. Nature Reviews Clinical Oncology
- Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy
- (2019) Pengfei Zhao et al. Journal of Hematology & Oncology
- Response to targeted therapy or chemotherapy following immunotherapy in patients with gastrointestinal cancers - a case series
- (2019) Rayan Alsuwaigh et al. Journal for ImmunoTherapy of Cancer
- Rapid disease progression in patient with mismatch-repair deficiency pituitary ACTH-secreting adenoma treated with checkpoint inhibitor pembrolizumab
- (2019) Mario Caccese et al. ANTI-CANCER DRUGS
- Mechanisms regulating PD-L1 expression on tumor and immune cells
- (2019) Shuming Chen et al. Journal for ImmunoTherapy of Cancer
- Emerging predictors of the response to the blockade of immune checkpoints in cancer therapy
- (2018) Xiaolei Li et al. Cellular & Molecular Immunology
- Aggressive and malignant pituitary tumours: state-of-the-art
- (2018) Dorota Dworakowska et al. ENDOCRINE-RELATED CANCER
- Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016
- (2018) Ann McCormack et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Tumor Mutation Burden: Leading Immunotherapy to the Era of Precision Medicine?
- (2018) Conor E. Steuer et al. JOURNAL OF CLINICAL ONCOLOGY
- The expression profile of PD-L1 and CD8+ lymphocyte in pituitary adenomas indicating for immunotherapy
- (2018) Peng-fei Wang et al. JOURNAL OF NEURO-ONCOLOGY
- PD-L1 Expression Heterogeneity in Non–Small Cell Lung Cancer: Defining Criteria for Harmonization between Biopsy Specimens and Whole Sections
- (2018) Enrico Munari et al. Journal of Thoracic Oncology
- Increased Response Rates to Salvage Chemotherapy Administered after PD-1/PD-L1 Inhibitors in Patients with Non–Small Cell Lung Cancer
- (2018) Song Ee Park et al. Journal of Thoracic Oncology
- Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
- (2018) Dai Fukumura et al. Nature Reviews Clinical Oncology
- Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
- (2018) Mark A. Socinski et al. NEW ENGLAND JOURNAL OF MEDICINE
- Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens
- (2018) Romualdo Barroso-Sousa et al. JAMA Oncology
- Marked response of a hypermutated adrenocorticotropic hormone-secreting pituitary carcinoma to ipilimumab and nivolumab
- (2018) Andrew L Lin et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors
- (2018) Ming Yi et al. Molecular Cancer
- Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors
- (2018) Daniel Y. Wang et al. JAMA Oncology
- Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
- (2018) T A Chan et al. ANNALS OF ONCOLOGY
- Long-Term Survival After Transformation of an Adrenocorticotropic Hormone–Secreting Pituitary Macroadenoma to a Silent Corticotroph Pituitary Carcinoma
- (2018) Lauren E. Rotman et al. World Neurosurgery
- Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation
- (2017) David Miles et al. EUROPEAN JOURNAL OF CANCER
- European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas
- (2017) Gerald Raverot et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Prior irradiation results in elevated programmed cell death protein 1 (PD-1) in T cells
- (2017) Deguan Li et al. INTERNATIONAL JOURNAL OF RADIATION BIOLOGY
- Successful treatment of pituitary carcinoma with concurrent radiation, temozolomide, and bevacizumab after resection
- (2017) Waseem Touma et al. JOURNAL OF CLINICAL NEUROSCIENCE
- Response rates to single-agent chemotherapy after exposure to immune checkpoint inhibitors in advanced non-small cell lung cancer
- (2017) Gustavo Schvartsman et al. LUNG CANCER
- Detection of programmed death ligand 1 protein and CD8+ lymphocyte infiltration in plurihormonal pituitary adenomas
- (2017) Pengfei Wang et al. MEDICINE
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- (2017) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Excellent response to chemotherapy post immunotherapy
- (2017) Ashish D. Dwary et al. Oncotarget
- Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
- (2017) Zachary R. Chalmers et al. Genome Medicine
- Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group
- (2017) I. Puzanov et al. Journal for ImmunoTherapy of Cancer
- Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
- (2016) Jonathan E Rosenberg et al. LANCET
- Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial
- (2016) Padmanee Sharma et al. LANCET ONCOLOGY
- Predictive biomarkers for checkpoint inhibitor-based immunotherapy
- (2016) Geoffrey T Gibney et al. LANCET ONCOLOGY
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anti-PD-1 antitumor immunity is enhanced by local and abrogated by systemic chemotherapy in GBM
- (2016) D. Mathios et al. Science Translational Medicine
- Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma
- (2016) Jeffrey J. Wallin et al. Nature Communications
- Personalized Oncology Meets Immunology: The Path toward Precision Immunotherapy
- (2016) R. Mandal et al. Cancer Discovery
- Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors
- (2016) Yu Mei et al. Oncotarget
- Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors
- (2016) Claire F. Friedman et al. JAMA Oncology
- Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial
- (2015) Robert J. Motzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
- (2015) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- (2015) Edward B. Garon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights
- (2015) Alexander Faje Pituitary
- The expression profile of Dopamine D2 receptor, MGMT and VEGF in different histological subtypes of pituitary adenomas: a study of 197 cases and indications for the medical therapy
- (2014) Youwei Wang et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Pituitary Expression of CTLA-4 Mediates Hypophysitis Secondary to Administration of CTLA-4 Blocking Antibody
- (2014) S. Iwama et al. Science Translational Medicine
- Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma
- (2014) F. S. Hodi et al. Cancer Immunology Research
- Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment
- (2014) Stefani Spranger et al. Journal for ImmunoTherapy of Cancer
- AVEREL: A Randomized Phase III Trial Evaluating Bevacizumab in Combination With Docetaxel and Trastuzumab As First-Line Therapy for HER2-Positive Locally Recurrent/Metastatic Breast Cancer
- (2013) Luca Gianni et al. JOURNAL OF CLINICAL ONCOLOGY
- Normalizing Tumor Microenvironment to Treat Cancer: Bench to Bedside to Biomarkers
- (2013) Rakesh K. Jain JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab plus Ipilimumab in Advanced Melanoma
- (2013) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Predictive Impact of Circulating Vascular Endothelial Growth Factor in Four Phase III Trials Evaluating Bevacizumab
- (2012) P. S. Hegde et al. CLINICAL CANCER RESEARCH
- Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Biomarker Evaluation From the AVAGAST Randomized Phase III Trial
- (2012) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Over-expression of vascular endothelial growth factor in pituitary adenomas is associated with extrasellar growth and recurrence
- (2012) Ruth Sánchez-Ortiga et al. Pituitary
- A Mechanism of Acquiring Temozolomide Resistance During Transformation of Atypical Prolactinoma Into Prolactin-Producing Pituitary Carcinoma: Case Report
- (2011) Mineko Murakami et al. NEUROSURGERY
- Anti-VEGF therapy in pituitary carcinoma
- (2011) Leon D. Ortiz et al. Pituitary
- VEGF and CD31 Association in Pituitary Adenomas
- (2010) Carolina Cristina et al. ENDOCRINE PATHOLOGY
- PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors
- (2010) M. A. Curran et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- MSH6 Mutations Arise in Glioblastomas during Temozolomide Therapy and Mediate Temozolomide Resistance
- (2009) S. Yip et al. CLINICAL CANCER RESEARCH
- Biomarkers of response and resistance to antiangiogenic therapy
- (2009) Rakesh K. Jain et al. Nature Reviews Clinical Oncology
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started